Antibody therapy targeting RSV's G protein to treat acute infection in children
Official title: Human Antibody for Acute Infection Treatment of RSV
Funded at Trellis Bioscience, INC. · NIH-11174002 · Data updated 2026-11-12
A patient-friendly immune therapy using a human monoclonal antibody (TRL3D3) aimed at treating RSV infection in young children by blocking the virus’s G protein.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trellis Bioscience, INC. NIH-funded |
| Lab location | 1 site (Redwood City, UNITED STATES) |
| Project start | August 1, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $999,759 |
| NIH project number | 1SB1AI191674-01 |
| Project ID | NIH-11174002 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are children with acute RSV infection who may be eligible for early-phase clinical trials of the TRL3D3 antibody.
✕Less likely to help
Very young children or those with RSV are not eligible yet until trials prove safety and efficacy.
What this research studies
This project focuses on preparing TRL3D3, a human monoclonal antibody, for clinical trials to treat acute RSV infection in children. It involves finishing the drug product and validating its analytical tests so it can be studied in people. If successful, this therapy could become a new option for treating RSV in kids who become sick, not just preventing infection. The work is centered at Trellis Bioscience in Redwood City and led by Dr. Lawrence Kauvar.
Why it matters
Potential benefit: If successful, children with RSV could receive a targeted therapy to reduce illness and complications from acute infection.
How similar studies have gone: This approach follows prior RSV antibody research but focuses on a new target (G protein) and acute treatment rather than prevention.
Where this research is happening
-
Trellis Bioscience, INC.
Redwood City, United States Active
Researchers
- Principal investigator: Kauvar, Lawrence Michael — Trellis Bioscience, INC.
- Study coordinator: Kauvar, Lawrence Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.